Literature DB >> 17068136

Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts.

Andrew G Gianoukakis1, Timothy A Jennings, Chris S King, Christine E Sheehan, Neil Hoa, Paraskevi Heldin, Terry J Smith.   

Abstract

Graves' disease (GD) and Hashimoto's thyroiditis (HT) are autoimmune processes often associated with hyperthyroidism and hypothyroidism, respectively. Despite their diverging clinical presentations, immune activation drives both diseases and results in connective tissue accumulation of the nonsulfated glycosaminoglycan, hyaluronan. The hydrophilic property of hyaluronan contributes to the pathogenesis of thyroid-associated ophthalmopathy, dermopathy and hypothyroid myxedema. Whether hyaluronan accumulates in the thyroid and plays a role in goiter formation in GD and HT remains unknown. We report here that levels of hyaluronan are increased in thyroid tissue from individuals with both diseases compared with glands uninvolved with autoimmune disorders. The transcript encoding hyaluronan synthase (HAS)-3, one of three mammalian HAS isoforms, was detected in thyroid tissue. Isolated thyrocytes in primary culture express all three HAS isoforms when treated with IL-1beta. Thyrocytes and thyroid fibroblasts produce hyaluronan under basal culture conditions and IL-1beta enhances levels of this molecule in both cell types. On a per-cell basis, fibroblasts produce more hyaluronan than do thyrocytes under basal conditions and after cytokine treatment. Synthesis in thyrocytes can also be altered by increasing serum concentration in the medium and by modifying culture density. Our findings suggest that hyaluronan accumulation in thyroid tissue might derive from thyrocytes and fibroblasts. Moreover, this glycosaminoglycan becomes more abundant as a consequence of autoimmune disease. It may therefore contribute to increased thyroid volume in GD and HT. Coupled with the newly identified influence exerted by hyaluronan on immunocompetent cells, our findings represent potentially important insights into the pathogenesis of autoimmune thyroid diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068136     DOI: 10.1210/en.2006-0736

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 2.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

Review 3.  Hyaluronan in immune dysregulation and autoimmune diseases.

Authors:  Nadine Nagy; Hedwich F Kuipers; Payton L Marshall; Esther Wang; Gernot Kaber; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-04-04       Impact factor: 11.583

4.  Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control.

Authors:  Nadine Nagy; Vivekananda G Sunkari; Gernot Kaber; Sonia Hasbun; Dung N Lam; Cate Speake; Srinath Sanda; Tracey L McLaughlin; Thomas N Wight; Steven R Long; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-09-06       Impact factor: 11.583

5.  Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease.

Authors:  Naxin Guo; Carolyn J Baglole; Charles W O'Loughlin; Steven E Feldon; Richard P Phipps
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

6.  Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction.

Authors:  Lei Zhang; Timothy Bowen; Fiona Grennan-Jones; Carol Paddon; Peter Giles; Jason Webber; Robert Steadman; Marian Ludgate
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

Review 7.  4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer.

Authors:  Nadine Nagy; Hedwich F Kuipers; Adam R Frymoyer; Heather D Ishak; Jennifer B Bollyky; Thomas N Wight; Paul L Bollyky
Journal:  Front Immunol       Date:  2015-03-23       Impact factor: 7.561

8.  Histopathological characteristics of larynx in hypothyroidism in an experimental rabbit model.

Authors:  Kamyar Iravani; Behnaz Golkhar; Negar Azarpira; Mahsa Kohandel-Shirazi; Mahjoob Vahedi
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-07-02

9.  HYPOTHYROIDISM COULD BE A POTENTIAL FACTOR TO PROLONG SUBCUTANEOUS NODULES OF EXENATIDE ONCE WEEKLY: A CASE REPORT.

Authors:  Ayako Ito; Akie Kamata; Aya Nozaki; Takao Ando; Atsushi Kawakami
Journal:  AACE Clin Case Rep       Date:  2019-04-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.